Chicago Atlantic (REFI) Q4 2025 earnings review
Massive Regulatory Catalyst Masking Stagnant Growth and Compressed Yields
Chicago Atlantic ended 2025 with a transformative macro tailwind but lackluster fundamental momentum. A December 2025 executive order to move cannabis to Schedule III dramatically improves borrower credit profiles by eliminating the 280E tax burden. However, REFI's actual Q4 numbers were soft. The portfolio is stable, barely growing to $411.1M from $410.2M a year ago, as high prepayments offset new originations. More concerningly, portfolio yield compressed to 16.3%, causing Distributable EPS to decelerate to $0.43—falling short of the $0.47 regular dividend for the first time in recent quarters.
🐂 Bull Case
The December 2025 executive order to reschedule cannabis, alongside the federal ban on unregulated intoxicating hemp-derived THC, permanently alters the landscape. Regulated operators will see massive cash flow boosts (no 280E tax) and reduced illicit competition, drastically lowering REFI's default risk.
The near-term investment pipeline accelerated to $616M (up from $441M in Q3). With $52.9M available on the revolver and $51.1M already advanced in early 2026, the company is primed to deploy capital into stronger borrowers.
🐻 Bear Case
Q4 diluted Distributable EPS dropped to $0.43, failing to cover the $0.47 regular dividend. This reversing trend erodes book value, which has already decelerated from $14.83 at 24Q4 to $14.60 today.
Gross unlevered yield to maturity (YTM) has been decelerating consistently, dropping from 17.2% in 24Q4 to 16.3% in 25Q4, putting structural pressure on net interest income unless leverage is significantly increased.
⚖️ Verdict: ⚪
Neutral. The macro tailwinds from Schedule III are undeniable and make the existing portfolio incredibly safe. However, the financial reality is that REFI is struggling to organically grow its portfolio net of prepayments, and yield compression is causing earnings to slip below the dividend threshold.
Key Themes
Macro: President Orders Rescheduling (Schedule III)
The December 2025 executive order directing agencies to reclassify cannabis to Schedule III is a monumental catalyst. Once enacted, this eliminates the crushing 280E tax burden. Management notes this improves revenue visibility, strengthens operator balance sheets, supports higher equity valuations, and creates accretive refinancing opportunities without necessarily flooding the space with new traditional bank lenders.
Interest Rate Insulation Protects Downside
Despite a declining rate environment, REFI's portfolio is stable and highly protected. Over 90% of the portfolio is insulated from additional interest rate declines through a mix of fixed-rate structures (37.6%) and floating-rate loans with rate floors at or above 6.75% (48.2%).
High Prepayment Velocity Stifles Net Growth
Management touted completing 2025 with 'net portfolio growth,' but the data shows total loan principal only grew from $410.2M in 24Q4 to $411.1M in 25Q4. The robust pipeline is constantly fighting high prepayments. For example, subsequent to year-end, REFI advanced $51.1M but immediately saw $40.4M in repayments (including $32.9M in full loan prepayments). Growth is effectively stable, not accelerating.
Structural Yield Compression
A specific data point contradicting the positive growth narrative is the steady deceleration of portfolio yields. Gross unlevered weighted average yield to maturity has fallen for four consecutive quarters, landing at 16.3% (down 90 bps YoY). This compression—likely due to prime rate cuts and increased competition for high-quality borrowers—directly caused Q4 Distributable EPS ($0.43) to miss the dividend payout ($0.47).
ESOP and Delayed Draw Financing Vehicles
To capture market share in a capital-starved environment, REFI is leveraging specific loan products like Employee Stock Ownership Plan (ESOP) financing and Delayed Draw Term Loans. The latter accounted for $34.9M of the $51.1M advanced subsequent to quarter-end, providing a predictable, milestone-based deployment channel for the existing borrower base.
Other KPIs
Decelerating. Dropped from $14.71 in Q3 and $14.83 a year ago. Paying dividends that exceed basic GAAP Net Income ($0.38) and Distributable Earnings ($0.43 diluted) directly cannibalizes book value.
Stable. As of March 12, 2026, the company has $52.9M available on its secured revolving credit facility, leaving ~$50M in net liquidity to tackle the $616M near-term pipeline.
Stable. Down slightly from 33.7% in 24Q4 and 32.8% in 25Q3. The balance sheet remains highly conservative compared to traditional commercial mortgage REITs, leaving significant room to lever up if high-quality loans materialize.
Guidance
Stable. Management expects to maintain this payout ratio based on Distributable Earnings. Given that Q4 Distributable EPS was $0.44 (basic) and the dividend is currently $0.47, this implies either the dividend will need to be cut or earnings must accelerate sequentially in early 2026.
Key Questions
Dividend Sustainability
Q4 Distributable EPS dropped to $0.43 (diluted), failing to cover the $0.47 regular dividend, which contributed to Book Value per share slipping to $14.60. If yields continue compressing, will you reduce the regular dividend to protect Book Value?
Yield Floor
Gross unlevered YTM has decelerated steadily from 17.2% to 16.3% over the last year. With the Schedule III announcement inherently lowering the risk profile of operators, should investors expect a rapid 'normalization' of yields down into the 12-14% range as traditional capital tests the waters?
Pipeline Conversion Bottleneck
You highlight an impressive $616M pipeline, yet the net loan portfolio only grew by $0.9M for the entire year due to heavy prepayments. What specific strategies are in place to ensure you capture net growth rather than just replacing churning assets?